Status:
RECRUITING
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
United States Department of Defense
Conditions:
Cancer Diagnosis
Eligibility:
All Genders
45+ years
Phase:
NA
Brief Summary
The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to de...
Detailed Description
This research study aims to assess the performance of the Galleri multi-cancer early detection (MCED) screening test in a military population and to compare the number and types of cancers diagnosed u...
Eligibility Criteria
Inclusion
- Active-duty or National Guard/Reserves military service for eight or more years
- Age ≥ 45
- Received care at a VA facility within past 5 years
- Able to sign informed consent
- Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy
Exclusion
- Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable)
- Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable)
- Individuals in the process of being evaluated for a clinical suspicion of cancer
Key Trial Info
Start Date :
March 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2028
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT06523868
Start Date
March 31 2025
End Date
September 30 2028
Last Update
April 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215